Cargando…

Treatment of Advanced Renal Cell Carcinoma: Immunotherapies Have Demonstrated Overall Survival Benefits While Targeted Therapies Have Not

CONTEXT: Current guidelines suggest several targeted therapies (TTs) and immunotherapies (ITs) in the treatment of advanced or metastatic renal cell carcinoma (mRCC). Ideal sequencing of these treatments is unclear. OBJECTIVE: The primary objective was to evaluate the overall survival (OS) data of t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hemminki, Otto, Perlis, Nathan, Bjorklund, Johan, Finelli, Antonio, Zlotta, Alexandre R., Hemminki, Akseli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Review – Kidney Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317793/ https://www.ncbi.nlm.nih.gov/pubmed/34337479 http://dx.doi.org/10.1016/j.euros.2020.11.003

Ejemplares similares

Second Primary Cancers After Kidney Cancers, and Kidney Cancers as Second Primary Cancers
por: Zheng, Guoqiao, et al.
Publicado: (2021)

Local Treatment of Recurrent Renal Cell Carcinoma May Have a Significant Survival Effect Across All Risk-of-recurrence Groups
por: Marconi, Lorenzo, et al.
Publicado: (2022)

Effect of Inferior Vena Cava Tumor Thrombus on Overall Survival in Metastatic Renal Cell Carcinoma Patients Treated with Cytoreductive Nephrectomy
por: Hoeh, Benedikt, et al.
Publicado: (2022)

Survival in colon and rectal cancers in Finland and Sweden through 50 years
por: Hemminki, Kari, et al.
Publicado: (2021)

Oncolytic viruses for cancer immunotherapy
por: Hemminki, Otto, et al.
Publicado: (2020)

Oncolytic Immunotherapy: Where Are We Clinically?
por: Hemminki, Akseli
Publicado: (2014)

Second primary cancer after female breast cancer: Familial risks and cause of death
por: Zheng, Guoqiao, et al.
Publicado: (2018)

Rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor
por: Zheng, Guoqiao, et al.
Publicado: (2020)

RPN (Radius, Position of tumour, iNvasion of renal sinus) Classification and Nephrometry Scoring System: An Internationally Developed Clinical Classification To Describe the Surgical Difficulty for Renal Masses for Which Robotic Partial Nephrectomy Is Planned
por: Agarwal, Dinesh K., et al.
Publicado: (2023)

Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in the Management of Oligometastatic Renal Cell Carcinoma
por: Udovicich, Cristian, et al.
Publicado: (2022)

Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden
por: Hemminki, Kari, et al.
Publicado: (2021)

Utilization of Renal Mass Biopsy for T1 Renal Lesions across Michigan: Results from MUSIC-KIDNEY, A Statewide Quality Improvement Collaborative
por: Patel, Amit K., et al.
Publicado: (2021)

Differentiating Oncocytic Renal Tumors from Chromophobe Renal Cell Carcinoma: Comparison of Peak Early-phase Enhancement Ratio to Clinical Risk Factors and Rater Predictions
por: Patel, Hiten D., et al.
Publicado: (2022)

New-onset Chronic Kidney Disease After Surgery for Localised Renal Masses in Patients with Two Kidneys and Preserved Renal Function: A Contemporary Multicentre Study
por: Pecoraro, Alessio, et al.
Publicado: (2023)

The Metastatic Risk of Renal Cell Carcinoma by Primary Tumor Size and Subtype
por: Monda, Steven M., et al.
Publicado: (2023)

Effectiveness of Thermal Ablation for Renal Cell Carcinoma after Prior Partial Nephrectomy
por: Abdelsalam, Mohamed E., et al.
Publicado: (2023)

Characterizing Tumor Thrombus Arising from Non–Clear Cell Renal Cell Carcinoma
por: Rabinowitz, Matthew J., et al.
Publicado: (2022)

Systematic Evaluation of the Prognostic Impact and Intratumour Heterogeneity of Clear Cell Renal Cell Carcinoma Biomarkers
por: Gulati, Sakshi, et al.
Publicado: (2014)

Counterbalancing COVID-19 with Cancer Surveillance and Therapy: A Survey of Patients with Renal Cell Carcinoma
por: Staehler, Michael, et al.
Publicado: (2021)

Defining Tumour Shape Irregularity for Preoperative Risk Stratification of Clinically Localised Renal Cell Carcinoma
por: Tanaka, Hajime, et al.
Publicado: (2022)

Infiltration of M2 Macrophages and Regulatory T Cells Plays a Role in Recurrence of Renal Cell Carcinoma
por: Davidsson, Sabina, et al.
Publicado: (2020)

Real-world Treatment Patterns and Clinical Outcomes for Metastatic Renal Cell Carcinoma in the Current Treatment Era
por: Shah, Neil J., et al.
Publicado: (2023)

Benefit and Harm of Active Surveillance for Biopsy-proven Renal Oncocytoma: A Systematic Review and Pooled Analysis
por: Baboudjian, Michael, et al.
Publicado: (2022)

Clinical T1a Renal Cell Carcinoma, Not Always a Harmless Disease—A National Register Study
por: Almdalal, Tarik, et al.
Publicado: (2022)

Plasma and Urine Free Glycosaminoglycans as Monitoring Biomarkers in Nonmetastatic Renal Cell Carcinoma—A Prospective Cohort Study
por: Gatto, Francesco, et al.
Publicado: (2022)

Assessment of the VENUSS and GRANT Models for Individual Prediction of Cancer-specific Survival in Surgically Treated Nonmetastatic Papillary Renal Cell Carcinoma
por: Piccinelli, Mattia L., et al.
Publicado: (2023)

Selective Use of Neoadjuvant Targeted Therapy Is Associated with Greater Achievement of Partial Nephrectomy for High-complexity Renal Masses in a Solitary Kidney
por: Attawettayanon, Worapat, et al.
Publicado: (2023)

Initial Observation of a Large Proportion of Patients Presenting with Clinical Stage T1 Renal Masses: Results from the MUSIC-KIDNEY Statewide Collaborative
por: Patel, Amit K., et al.
Publicado: (2020)

Impact of Body Mass Index on Survival Outcomes of Patients with Metastatic Renal Cell Carcinoma in the Immuno-oncology Era: A Systematic Review and Meta-analysis
por: Takemura, Kosuke, et al.
Publicado: (2022)

In Situ Metabolomics Expands the Spectrum of Renal Tumours Positive on (99m)Tc-sestamibi Single Photon Emission Computed Tomography/Computed Tomography Examination
por: Papathomas, Thomas, et al.
Publicado: (2020)

Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) for Lenvatinib plus Everolimus Versus Everolimus Monotherapy in Patients with Advanced Renal Cell Carcinoma
por: Lee, Chung-Han, et al.
Publicado: (2021)

Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study
por: Lindskog, Magnus, et al.
Publicado: (2022)

Randomized Clinical Trial Comparing On-clamp Versus Off-clamp Laparoscopic Partial Nephrectomy for Small Renal Masses (CLOCK II Laparoscopic Study): A Intention-to-treat Analysis of Perioperative Outcomes
por: Bertolo, Riccardo, et al.
Publicado: (2022)

Types of second primary cancer influence overall survival in cutaneous melanoma
por: Zheng, Guoqiao, et al.
Publicado: (2021)

Incidence trends in bladder and lung cancers between Denmark, Finland and Sweden may implicate oral tobacco (snuff/snus) as a possible risk factor
por: Hemminki, Kari, et al.
Publicado: (2021)

Survival in bladder and upper urinary tract cancers in Finland and Sweden through 50 years
por: Hemminki, Kari, et al.
Publicado: (2022)

Long-term survival trends for primary liver and pancreatic cancers in the Nordic countries
por: Hemminki, Kari, et al.
Publicado: (2022)

Survival in gastric and esophageal cancers in the Nordic countries through a half century
por: Hemminki, Kari, et al.
Publicado: (2023)

Survival in Lung Cancer in the Nordic Countries Through A Half Century
por: Tichanek, Filip, et al.
Publicado: (2023)

Survival in melanoma in the nordic countries into the era of targeted and immunological therapies
por: Tichanek, Filip, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6u20bgmfb8hi7kf43gi7reb4hf